UHC Medicare Advantage plans in NGS states expand access via NPPs UHC Medicare Advantage plans in NGS states expand access via NPPs

Link:
Neuronetics Announces Expanded TMS Access through United HealthCare

28 April 2023

Go here to see the original:
Preliminary Results for the Year Ended 31 December 2022

Conference call to be held Monday, May 1, 2023, at 8:30 AM ET Conference call to be held Monday, May 1, 2023, at 8:30 AM ET

See more here:
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

TORONTO, April 28, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2023 Annual Meeting of Shareholders on Thursday, June 22, 2023, at 11:00 a.m. ET.

Original post:
Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders

HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023.

The rest is here:
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events

View post:
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with...

LA JOLLA, Calif., April 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of advanced nonalcoholic steatohepatitis (NASH).

See original here:
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial Officer. He will continue to also serve as the company’s China General Manager.

Read more from the original source:
LianBio Promotes Pascal Qian to Chief Commercial Officer

The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™

Read this article:
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™

More here:
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression